| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 2 Results |
| Timing: | H1 2017 |
| Designation(s): | None |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Other |
| Indication: | IgG4-RD |
| Lead Indication?: | No |
| Treatment Name: | XmAb5871 |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | Xencor |
| Stock Symbol: | XNCR |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | http://investors.xencor.com/releasedetail.cfm?ReleaseID=977312 |
| Partnership: | No |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
QuoteXmAb5871 is a first-in-class monoclonal antibody that targets CD19 with its variable domain and that uses Xencor's XmAb immune inhibitor Fc domain to target FcγRIIb, a receptor that inhibits B-cell function. In March 2016, Xencor initiated a Phase 2 clinical study for the treatment of IgG4-RD and a Phase 2 clinical study for the treatment of SLE.
Today, Xencor will discuss the trial design of its ongoing Phase 2 studies in IgG4-RD and SLE. Initial data from the IgG4-RD trial is expected in the first half of 2017 and initial data from the SLE trial is expected in 2018. A Phase 1 study with a subcutaneous formulation of XmAb5871 is expected to begin this year with initial data expected in 2017.